What do systematic reviews say?

Naftopidil vs silodosin (alpha‐blocker)

Naftopidil probably leads to lower sexual adverse events compared with silodosin (alpha‐blocker) (moderate certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.15 [0.06, 0.42]
  4 studies · 348 participants
  Moderate

Naftopidil vs tamsulosin

Naftopidil showed no clear difference in sexual adverse events compared with tamsulosin (alpha‐blocker) (low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.54 [0.24, 1.22]
  5 studies · 397 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  GRADE not reported

Silodosin vs naftopidil

Silodosin probably leads to higher sexual adverse events compared with naftopidil (moderate certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 5.93 [2.16, 16.29]
  4 studies · 405 participants
  Moderate